1. Identification of bioactive compounds in Brassica oleracea var. capitata L. with enzyme-inhibitory activity against postprandial hyperglycemia.
- Author
-
Uuh Narvaez JJ, Moguel Ojeda GE, Guerrero-Analco JA, Monribot-Villanueva JL, Vidal-Limon A, Melgar Lalanne G, Rojas Herrera R, and Segura Campos MR
- Subjects
- Molecular Structure, Glycoside Hydrolase Inhibitors pharmacology, Glycoside Hydrolase Inhibitors isolation & purification, alpha-Glucosidases metabolism, Molecular Docking Simulation, Hypoglycemic Agents pharmacology, Brassica chemistry, Hyperglycemia drug therapy, Phytochemicals pharmacology, Phytochemicals isolation & purification, alpha-Amylases antagonists & inhibitors, alpha-Amylases metabolism
- Abstract
Postprandial hyperglycemia is a hallmark of diabetes, and inhibition of key carbohydrate digestion enzymes such as α-amylase (α-AMY) and α-glucosidase (α-GLU) is an effective therapeutic target. A potential unexplored source of inhibitory compounds of these enzymes is Brassica oleracea var. capitata L (BOCE). This study explored the in vitro inhibition mechanism of BOCE and studied in silico the interaction of its compounds identified and quantified by UPLC-QTOF-MS on α-AMY and α-GLU. BOCE demonstrated IC
50 values of 3.08 mg/mL for α-AMY and 22.63 mg/mL for α-GLU, indicating competitive and mixed-type inhibitions, respectively. Untargeted metabolomics identified 21 compounds, primarily phenolic acids such as t-cinnamic, sinapic, and caffeoylquinic acid. In the targeted analysis, 11 compounds were quantified, mainly phenolic acids. The most impactful biosynthetic pathways identified were phenylpropanoids and brassinosteroids. In silico analysis revealed that for α-AMY and α-GLU, castasterone and 26-hydroxybrassinolide displayed the lowest binding free energies with specific hydrogen bond patterns to catalytic residues in the binding site, respectively. B. oleracea is a promising source of compounds with the ability to modulate key enzymes related to hyperglycemia. Specifically, compounds such as castasterone and 26-hydroxybrassinolide show potential against α-AMY and α-GLU inhibition, offering a novel approach to diabetes., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2025
- Full Text
- View/download PDF